Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 13.10.2025 1 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Am J Respir Cell Mol Biol 1 Ann Surg Oncol 2 Ann Thorac Surg 4 BMC Cancer 1 Br J Cancer 2 Chest 2 Clin Lung Cancer 2 Clin Nucl Med 3 Eur J Cancer 5 Eur J Cardiothorac Surg 1 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 J Natl Cancer Inst 2 J Thorac Cardiovasc Surg 11 J Thorac Oncol 8 Lung Cancer 2 Nat Genet 2 Oncologist 3 PLoS One 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. JANG S, Kim J, Lee JS, Jeong Y, et al
   Real-World Diagnostic Performance and Clinical Utility of Artificial-Intelligence-Assisted Interpretation for Detection of Lung Metastasis on CT in Patients With Colorectal Cancer.
   AJR Am J Roentgenol. 2025 Jun 11. doi: 10.2214/AJR.25.33063.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. CUMMINGS AL, Sussell J, Rosettie KL, El Moustaid F, et al
   A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States.
   Am J Clin Oncol. 2025 Oct 8. doi: 10.1097/COC.0000000000001248.
   PubMed         Abstract available
   
   

   
   Am J Respir Cell Mol Biol

3. HUANG W, Bi B, Huang Q, Wu H, et al
   SART3 Activates CD36 Transcription by Recruiting FOXM1 and Activates PARP to Augment Cisplatin Resistance in Non-Small Cell Lung Cancer.
   Am J Respir Cell Mol Biol. 2025 Oct 10. doi: 10.1165/rcmb.2025-0319.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. MOTT NM, Meguid RA, Randhawa SK, David EA, et al
   ASO Visual Abstract: Social Vulnerability is Associated with Significant Delays to Definitive Surgery for Stage IA-IIIA Non-small Cell Lung Cancer and Consequential Increased Rates of Pathologic Upstaging.
   Ann Surg Oncol. 2025 Oct 7. doi: 10.1245/s10434-025-18504.
   PubMed        
   
   

   
   Ann Thorac Surg

5. WANG R, Wang Q, Xu R, Guo W, et al
   Objective Evaluation of Tubeless Thoracic Surgery in Early-stage Lung Cancer Patients Using Multi-modal Digital Device: A Prospective Study.
   Ann Thorac Surg. 2025 Oct 6:S0003-4975(25)00952.
   PubMed         Abstract available
   
   
6. PAN H, Tian Y, Chen H, Ge Z, et al
   Lobar versus Sub-Lobar Resection for Clinical Stage IA1-2 Non-Small Cell Lung Cancer with Tumor Spread Through Air Spaces.
   Ann Thorac Surg. 2025 Oct 4:S0003-4975(25)00909.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. WANGSUBTAWEE S, Thamrongjirapat T, Trachu N, Incharoen P, et al
   The impact of systemic inflammatory markers on EGFR-mutant non-small cell lung cancer.
   BMC Cancer. 2025;25:1510.
   PubMed         Abstract available
   
   
8. NAUREEN F, Shah Y, Rehman MU, Fazli Nasir FN, et al
   Innovative inhalable dry powder: nanoparticles loaded with Crizotinib for targeted lung cancer therapy.
   BMC Cancer. 2025;25:1526.
   PubMed         Abstract available
   
   
9. FANG J, Li Q, Xu N, Yang X, et al
   Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma.
   BMC Cancer. 2025;25:1543.
   PubMed         Abstract available
   
   
10. MORIKAWA K, Takashima Y, Oki M, Tsuzuku A, et al
    Prospective multicenter validation of a next-generation sequencing panel using cytology specimens for lung cancer: cPANEL.
    BMC Cancer. 2025;25:1538.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. ALHATTAB RAN, McKinley JM, Hunter RF, Delargy CM, et al
    Lung cancer burden attributable to ambient particulate matter: a nationally representative population-based case-control study.
    Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03207.
    PubMed         Abstract available
    
    

    
    Chest

12. CHOI JY, Rhee CK, Lee J
    Lung Cancer Risk in Preserved Ratio Impaired Spirometry and Airway Obstruction: A UK Biobank Study.
    Chest. 2025 Oct 8:S0012-3692(25)05501-1. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    
13. VAKIL E, Fortin M, Gonzalez AV, Samy L, et al
    Ultrathin Bronchoscopy With Radial Endobronchial Ultrasound and Rapid On-Site Evaluation for the Diagnosis of Peripheral Pulmonary Lesions: A Multicenter Randomized Controlled Factorial Trial.
    Chest. 2025;168:1034-1048.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

14. MATSUURA K, Komaki R, Kono M, Kudo T, et al
    A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution.
    Clin Lung Cancer. 2025 Sep 19:S1525-7304(25)00228.
    PubMed         Abstract available
    
    
15. GADGEEL SM, Nagasaka M, Dziubek K, Braun T, et al
    Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC).
    Clin Lung Cancer. 2025 Oct 3:S1525-7304(25)00227.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

16. ZHANG N, Li L, Liu H, Xu T, et al
    Increased Uptake of 68 Ga-DOTA-IBA in Lung NUT Carcinoma.
    Clin Nucl Med. 2025;50:1074-1075.
    PubMed         Abstract available
    
    
17. LIN X, Zhang G
    Biceps Brachii Metastasis as the Initial Clinical Manifestation of Lung Squamous Cell Carcinoma: A Potential Pitfall in Patients With Nonrespiratory Symptoms.
    Clin Nucl Med. 2025;50:1091-1092.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

18. HOUDA I, Naves D, Ulas EB, Lissenberg-Witte BI, et al
    Survival outcomes with carboplatin versus cisplatin and the impact of COVID-19 on platinum choice: A nationwide Netherlands registry study in small cell lung cancer patients (CACIS).
    Eur J Cancer. 2025;230:116042.
    PubMed         Abstract available
    
    
19. GUO J, Yao W, You Y
    Letter Re: Intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small-cell lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group stu
    Eur J Cancer. 2025;230:116023.
    PubMed        
    
    
20. TSUKAGUCHI A, Matsumoto K, Tamiya A, Tamiya M, et al
    Corrigendum to "Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study" [Eur J Cancer. 2025;228:115748].
    Eur J Cancer. 2025;230:116010.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

21. LIU X, Xing H, Wang Z
    Risk of Air Embolism and On-site Management during Intraoperative Lung Nodule Localization in Hybrid Room: 7 Cases from a Single Institute.
    Eur J Cardiothorac Surg. 2025;67:ezaf301.
    PubMed         Abstract available
    
    
22. WRIGHT GM, Egan AJM, Mack JM, Clatworthy S, et al
    PHASE 2 dose ranging trial of VGT-309 for molecular imaging of cancer during pulmonary resection.
    Eur J Cardiothorac Surg. 2025 Sep 23:ezaf314. doi: 10.1093.
    PubMed         Abstract available
    
    
23. KAMIGAICHI A, Mimae T, Tsubokawa N, Miyata Y, et al
    Recurrence risk stratification by station- and zone-based nodal classification in resected non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Oct 9:ezaf338. doi: 10.1093.
    PubMed         Abstract available
    
    
24. PETRONCINI M, Lucien A, Gherzi L, Daffre E, et al
    The geographical deprivation index is independently associated with all-case long-term mortality in resectable lung cancer.
    Eur J Cardiothorac Surg. 2025 Oct 9:ezaf339. doi: 10.1093.
    PubMed         Abstract available
    
    
25. GREIF K, Herrmann D, Kaya TB, Milobinski K, et al
    Value of Video-Assisted Mediastinal Lymphadenectomy in Mediastinal Staging in Non-Small Cell Lung Cancer Patients.
    Eur J Cardiothorac Surg. 2025 Oct 10:ezaf347. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Cancer

26. EFIL SC, Ozsan Celebi SN, Ozturk B, Bilgin B, et al
    Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study.
    Int J Cancer. 2025 Oct 4. doi: 10.1002/ijc.70169.
    PubMed         Abstract available
    
    

    
    Int J Oncol

27. LI X, Wang J, Ge W, Chen X, et al
    Exosomal microRNAs: A new role in the diagnosis and treatment of lung cancer metastases (Review).
    Int J Oncol. 2025;67:101.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

28. TOM MC, Wang K, Edwards DM, Huang J, et al
    Electrifying Results? Tumor Treating Fields Reduce Intracranial Relapse of Non-Small Cell Lung Cancer Brain Metastasis Following Radiosurgery in the METIS Trial.
    Int J Radiat Oncol Biol Phys. 2025 Oct 1:S0360-3016(25)06224.
    PubMed        
    
    

    
    J Natl Cancer Inst

29. KHOR S, Carlson JJ, Basu A, Bansal A, et al
    The association between new cancer therapy innovations and financial toxicity.
    J Natl Cancer Inst. 2025;117:2021-2028.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

30. WERNER R, Antonoff MB
    Reply: Selecting patients and tailoring surgical extent in stage IV non - small cell lung cancer.
    J Thorac Cardiovasc Surg. 2025 Oct 3:S0022-5223(25)00755.
    PubMed        
    
    
31. WU Q, Fan Z, Su H, Lei T, et al
    Refining surgical decision-making for high-risk stage IA Non-Small cell lung cancer.
    J Thorac Cardiovasc Surg. 2025 Oct 7:S0022-5223(25)00769.
    PubMed        
    
    

    
    J Thorac Oncol

32. YAO Z, Tang M, Jin Y, Ruan J, et al
    Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor-Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development
    J Thorac Oncol. 2025;20:1531-1537.
    PubMed         Abstract available
    
    
33. ZHOU F, Zhang J, Ren S, Chen J, et al
    Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone.
    J Thorac Oncol. 2025;20:1475-1488.
    PubMed         Abstract available
    
    
34. LEIGHL NB, Paz-Ares L, Abreu DR, Hui R, et al
    LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.
    J Thorac Oncol. 2025;20:1489-1504.
    PubMed         Abstract available
    
    
35. RIELY GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, et al
    Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.
    J Thorac Oncol. 2025;20:1538-1547.
    PubMed         Abstract available
    
    
36. CHO BC, Li W, Spira AI, Sauder M, et al
    Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
    J Thorac Oncol. 2025;20:1517-1530.
    PubMed         Abstract available
    
    
37. GAO BY, Lee YT
    Recalibrating Low-Dose Computed Tomography Lung Cancer Screening: Overdiagnosis, Access, and Equity.
    J Thorac Oncol. 2025;20:e103-e104.
    PubMed        
    
    
38. XIE D, Xu W
    Response to the Letter to the Editor: "Recalibrating Low-Dose Computed Tomography Lung Cancer Screening: Overdiagnosis, Access, and Equity".
    J Thorac Oncol. 2025;20:e104-e105.
    PubMed        
    
    
39. WU Y, Liang Y, Liang J
    Exploring the Impact of Comorbidities on Lung Cancer Screening Mortality Benefits: Insights and Suggestions for Methodological Enhancement.
    J Thorac Oncol. 2025;20:e111-e112.
    PubMed        
    
    
40. GENDARME S, Chouaid C, Ostrin E
    Comorbidities in Lung Cancer Screening: A Key to Finding the Right Spot or Opening Pandora's Box?
    J Thorac Oncol. 2025;20:e112-e113.
    PubMed        
    
    
41. ZHAO D, Li W, Li W
    Screening for Lung Cancer, Overdiagnosis, and Health Care Utilization: A Nationwide Population-Based Study.
    J Thorac Oncol. 2025;20:e114-e115.
    PubMed        
    
    
42. KIM SY, Silvestri GA, Park YS
    A Response to Letter to the Editor: "Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study".
    J Thorac Oncol. 2025;20:e115-e116.
    PubMed        
    
    

    
    Lung Cancer

43. REGUART N, Sampietro-Colom L, Juan-Vidal O, Aguilo M, et al
    Corrigendum to "Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)" [Lung Cancer 206 (2025) 108677].
    Lung Cancer. 2025 Oct 8:108790. doi: 10.1016/j.lungcan.2025.108790.
    PubMed        
    
    
44. MURATA D, Azuma K, Murotani K, Ito K, et al
    Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study.
    Lung Cancer. 2025;209:108772.
    PubMed         Abstract available
    
    
45. GUERRERA F, Gallina FT, Balzani E, Ambrosi F, et al
    Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials.
    Lung Cancer. 2025;209:108760.
    PubMed         Abstract available
    
    
46. CHENG WP, Lai CY, Lai HC, Liu JF, et al
    Efficacy and safety of taxane versus gemcitabine for advanced stage lung squamous cell carcinoma in global EHR-based retrospective cohorts: A pairwise propensity score-matched comparison.
    Lung Cancer. 2025;208:108751.
    PubMed         Abstract available
    
    
47. MELOSKY B, Chu QSC, Juergens RA, Snow S, et al
    Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.
    Lung Cancer. 2025;208:108717.
    PubMed         Abstract available
    
    
48. SMESSEIM I, Pennycuick A, van Boerdonk RA, Janes SM, et al
    Management of high-grade pre-invasive endobronchial lesions: To treat or not to treat?
    Lung Cancer. 2025;208:108757.
    PubMed         Abstract available
    
    
49. LI R, Xie W, Chen R, Wu J, et al
    The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.
    Lung Cancer. 2025;208:108698.
    PubMed         Abstract available
    
    
50. YU J, Shen X, Wen J, Chen T, et al
    Prognostic impact and characteristics of ROS1 fusion in patients with surgically resected lung adenocarcinoma.
    Lung Cancer. 2025;208:108743.
    PubMed         Abstract available
    
    

    
    Nat Genet

51. AUNG TN, Monkman J, Warrell J, Vathiotis I, et al
    Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer.
    Nat Genet. 2025;57:2482-2493.
    PubMed         Abstract available
    
    
52. DANOVI S
    Basal cells drive small cell lung cancer plasticity.
    Nat Genet. 2025;57:2349.
    PubMed        
    
    

    
    Oncologist

53. SYAL A, Meyer ML, Angelino K, Osei N, et al
    Antibody Drugs Conjugates in Non-Small Cell Lung Cancer: Current Status and Challenges.
    Oncologist. 2025 Oct 6:oyaf331. doi: 10.1093.
    PubMed         Abstract available
    
    
54. SYAL A, Meyer ML, Angelino K, Osei N, et al
    Antibody Drugs Conjugates in Small-Cell Lung Cancer: Present-Day Status and Promises.
    Oncologist. 2025 Oct 6:oyaf332. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

55. ZHANG X, Lin J, Fan Z, Zhang S, et al
    The role of lncRNA SNHG15 in UV-induced DNA damage repair.
    PLoS One. 2025;20:e0334414.
    PubMed         Abstract available
    
    
56. BAEISSA HM, Bakhsh T, Shakoori AM, Sindi G, et al
    Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins.
    PLoS One. 2025;20:e0334013.
    PubMed         Abstract available
    
    
57. NOMORI H, Yue C, Iguchi H, Kashihara K, et al
    Long-term outcomes of combination therapy with stereotactic body radiation therapy plus cryoablation using liquid nitrogen for stage I non-small cell lung cancer with tumors >/=2 cm.
    PLoS One. 2025;20:e0332893.
    PubMed         Abstract available
    
    

    
    Thorax

58. GOODLEY P, Crosbie PAJ
    Improving lung cancer screening: the role and challenges of risk prediction models.
    Thorax. 2025 Oct 5:thorax-2025-223605. doi: 10.1136/thorax-2025-223605.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.